Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Learn more about Juan and his recap of 2022 at GenomSys and his outlook for 2023 for himself and the company through the following quick questions:

GenomSys - JuanGood morning Juan and happy New Year. Starting off easy, which fun-fact did you learn this year?

The last one I learned was that ducklings ‘ride’ the wave their mother is generating while swimming so that the drag can carry them. This is essentially what cyclists do when racing, and they seem to do it instinctively.

What was your most outstanding achievement at GenomSys in 2022?

In 2022, together with the bioinformatics team, we extended GenomSys Variant Analyzer to perform Trio analysis and successfully completed the ISO certification to demonstrate the quality of the company and our solutions. This has been a big step towards making the benefits of MPEG-G available for clinical use. Now, clinicians can stop worrying about data processing to focus solely on finding the relevant variants and improving patients’ lives.

What was the most important thing you learned in 2022?

This year, I learned a lot about software development and how to work effectively and efficiently as a team that operates in a fast-paced environment. Also, I expanded my knowledge of blood groups and their related genetics, which has been quite exciting.

What are your expectations for you and/or GenomSys for 2023?

For 2023, with GenomSys Variant Analyzer 2.3.0, now including trio analysis and the launch of Blood Typer, I expect an increase in our user base. I will be happy to see more practical feedback from the end users that will allow us to further improve our pipelines with relevant features. I am also quite excited about new projects and collaborations coming in early 2023, so stay tuned!

If you have any further questions for Juan or about GenomSys, please feel free to contact us.

Schedule a call

[contact-form-7 id="224" title="contact call"]